Digestive Diseases and Sciences

, Volume 55, Issue 10, pp 2977–2981 | Cite as

Incidence, Severity, and Etiology of Drug-Induced Acute Pancreatitis

  • Ilona Vinklerová
  • Michal Procházka
  • Vlastimil Procházka
  • Karel Urbánek
Original Article



Drug-induced acute pancreatitis is considered to be a rare diagnosis. The incidence of drug-induced acute pancreatitis is usually estimated from case reports.


The aim of this study was to determine the incidence, etiology, and severity of drug-induced pancreatitis during a 2-year period in a tertiary hospital.


The study was conducted as a retrospective analysis of all cases of pancreatitis in the University Hospital in Olomouc (1,432 beds) in 2006–2007. All cases of acute pancreatitis were re-evaluated and divided according to the causative factor. In drug-induced cases, the WHO Probability Scale for the evaluation of causality relationship was used.


The inclusion criteria were met by 170 medical files. There were 91 (53%) cases in men and 79 (47%) in women, and mean age was 57 years old (5–91 years old). The etiology was in 53% biliary, 31% alcohol-induced, 12% other determined, and in 4% the cause could not be established. The proportion of drug-induced acute pancreatitis was 5.3% and it was the third most frequent cause of the AP. Azathioprine was the most frequent causative factor (three cases in two patients); all the other causative drugs were documented only in single cases: mesalazine, dexamethasone, ramipril, mycophenolate mofetil, cytarabine, and valproate.


The diagnosis of drug-induced acute pancreatitis seems to be underestimated because of the difficulties in determining the causative agent and the need for a retrospective re-evaluation of the suspected causative factors. The disease is more probable in younger persons, women, and patients suffering from Crohn’s disease.


Acute pancreatitis Drug-induced pancreatitis Adverse drug reactions Retrospective study Azathioprine Crohn’s disease 


  1. 1.
    McArthur KE. Review article: drug-induced pancreatitis. Aliment Pharmacol Ther. 1996;10(1):23–38.CrossRefPubMedGoogle Scholar
  2. 2.
    Mallory A, Kern F Jr. Drug-induced pancreatitis: a critical review. Gastroenterology. 1980;78:813–820.PubMedGoogle Scholar
  3. 3.
    Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol. 2005;39(8):709–716.CrossRefPubMedGoogle Scholar
  4. 4.
    Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol. 2007;5(6):648–661.CrossRefPubMedGoogle Scholar
  5. 5.
    Banks PA, Freeman ML, The Practice Parameter Committee of the American College of Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101:2379–2400.Google Scholar
  6. 6.
    Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255–1259.CrossRefPubMedGoogle Scholar
  7. 7.
    Mennecier D, Pons F, Arvers P, et al. Incidence and severity of non alcoholic and non biliary pancreatitis in a gastroenterology department. Gastroenterol Clin Biol. 2007;31(8-9 Pt 1):664–667.CrossRefPubMedGoogle Scholar
  8. 8.
    Balani AR, Grendell JH. Drug-induced pancreatitis. Incidence, management and prevention. Drug Safety. 2008;31(10):823–837.CrossRefPubMedGoogle Scholar
  9. 9.
    Lankisch PG, Droge M, Gottesleben F. Drug-induced acute pancreatitis: incidence and severity. Gut. 1995;37:565–567.CrossRefPubMedGoogle Scholar
  10. 10.
    Gullo L, Migliori M, Oláh A, et al. Acute pancreatitis in five European countries: etiology and mortality. Pancreas. 2002;24(3):223–227.CrossRefPubMedGoogle Scholar
  11. 11.
    Massironi S, Losco A, Basilisco G. Drug side-effects in IBD. Aliment Pharmacol Ther. 2002;16(10):1831.CrossRefPubMedGoogle Scholar
  12. 12.
    Moolsintong P, Loftus EV Jr, Chari ST, et al. Acute pancreatitis in patients with Crohn’s disease: clinical features and outcomes. Inflamm Bowel Dis. 2005;11(12):1080–1084.CrossRefPubMedGoogle Scholar
  13. 13.
    Barthet M, Lesavre N, Desplats S, et al. Frequency and characteristics of pancreatitis in patients with inflammatory bowel disease. Pancreatology. 2006;6(5):464–471.CrossRefPubMedGoogle Scholar
  14. 14.
    Bermejo F, Lopez-Sanroman A, Taxonera C, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther. 2008;28(5):623–628.CrossRefPubMedGoogle Scholar
  15. 15.
    Weersma RK, Peters FT, Oostenbrug LE, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn’s disease compared with other diseases. Aliment Pharmacol Ther. 2004;20(8):843–850.CrossRefPubMedGoogle Scholar
  16. 16.
    Bajaj JS, Saeian K, Varma RR, et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn’s disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol. 2005;100(5):1121–1125.CrossRefPubMedGoogle Scholar
  17. 17.
    Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51(4):536–539.CrossRefPubMedGoogle Scholar
  18. 18.
    Kanbay M, Korkmaz M, Yilmaz U, et al. Acute pancreatitis due to ramipril therapy. Postgrad Med J. 2004;80:617–618.CrossRefPubMedGoogle Scholar
  19. 19.
    Anagnostopoulos GK, Kostopoulos P, Tsiakos S, et al. Fulminant pancreatitis associated with ramipril therapy. Pancreas. 2003;27:278–279.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Ilona Vinklerová
    • 1
  • Michal Procházka
    • 1
  • Vlastimil Procházka
    • 1
  • Karel Urbánek
    • 2
  1. 1.2nd Department of Internal Medicine, Faculty of Medicine and University HospitalPalacký UniversityOlomoucCzech Republic
  2. 2.Department of Pharmacology, Faculty of Medicine and University HospitalPalacký UniversityOlomoucCzech Republic

Personalised recommendations